BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug ...
A new international study has delivered a rare dose of good news in the fight against aggressive brain tumors. Researchers found that a drug combination helped adults with recurrent grade 3 ...
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback